Shares of Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (TSE: AUP) received an average rating of “Hold” from the seven brokerages that currently cover the company, reports MarketBeat.com. One research analyst rated the stock with a sell rating, two assigned a conservation rating, and four issued a buy rating on the company. The year-over-year average price target among analysts who updated their stock coverage in the past year is $ 33.17.
AUPH has been the subject of several recent analyst reports. Oppenheimer increased its price target for Aurinia Pharmaceuticals from $ 32.00 to $ 33.00 and gave the stock a “market performance” rating in a research note on Thursday, November 4. Royal Bank of Canada raised its price target for Aurinia Pharmaceuticals from $ 23.00 to $ 34.00 and assigned the company an “outperformance” rating in a report released on Tuesday, October 26th. Zacks Investment Research downgraded Aurinia Pharmaceuticals from a “hold” rating to a “sell” rating in a report released on Monday, November 8. Bloom Burton began covering Aurinia Pharmaceuticals in a report on Friday, October 1. They issued a “conservation” rating and a price target of $ 23.00 for the company. Finally, SVB Leerink raised its price target on Aurinia Pharmaceuticals from $ 28.00 to $ 35 and gave the company an “outperformance” rating in a report released on Thursday, November 4.
NASDAQ: AUPH opened at $ 19.15 on Tuesday. Aurinia Pharmaceuticals has a one-year low at $ 9.72 and a one-year high at $ 33.97. The stock has a market cap of $ 2.46 billion, a price-to-earnings ratio of -15.83 and a beta of 0.66. The company has a fifty-day moving average of $ 24.44 and a 200-day moving average of $ 18.14.
Aurinia Pharmaceuticals (NASDAQ: AUPH) (TSE: AUP) last released its quarterly results on Tuesday, November 2. The biotech company reported ($ 0.39) earnings per share (EPS) for the quarter, missing ($ 0.06) Thomson Reuters consensus estimate of ($ 0.33). Aurinia Pharmaceuticals recorded a negative return on equity of 44.22% and a negative net margin of 215.58%. The company posted revenue of $ 14.67 million in the quarter, compared to the consensus estimate of $ 14.70 million. During the same period of the previous year, the company posted EPS ($ 0.28). Stock analysts expect Aurinia Pharmaceuticals to post -1.41 EPS for the current fiscal year.
Meanwhile, Executive Vice President Robert Bindert Huizinga sold 22,500 shares of the company in a transaction on Tuesday, September 14. The stock was sold for an average price of $ 21.75, for a total trade of $ 489,375.00. The transaction has been disclosed in a legal file with the Securities & Exchange Commission, which is available through this link. Additionally, insider Michael Robert Martin sold 90,000 shares of Aurinia Pharmaceuticals in a trade on Tuesday, September 14. The shares were sold for an average price of $ 21.19, for a total value of $ 1,907,100.00. Disclosure of this sale can be found here. In the past 90 days, insiders have sold 532,500 shares of the company valued at $ 13,931,100. 3.10% of the shares are held by insiders.
A number of hedge funds have recently bought and sold shares of AUPH. Cubist Systematic Strategies LLC increased its stake in Aurinia Pharmaceuticals by 109.5% during the first quarter. Cubist Systematic Strategies LLC now owns 3,889 shares of the biotech company valued at $ 50,000 after acquiring 2,033 additional shares in the last quarter. Patriot Financial Group Insurance Agency LLC increased its position in Aurinia Pharmaceuticals shares by 11.1% in the second quarter. Patriot Financial Group Insurance Agency LLC now owns 64,100 shares of the biotech company valued at $ 831,000 after acquiring an additional 6,425 shares in the last quarter. Advisor Group Holdings Inc. increased its position in Aurinia Pharmaceuticals shares by 77.0% in the second quarter. Advisor Group Holdings Inc. now owns 34,359 shares of the biotech company valued at $ 444,000 after acquiring an additional 14,946 shares in the last quarter. HighMark Wealth Management LLC acquired a new equity interest in Aurinia Pharmaceuticals in the second quarter valued at approximately $ 614,000. Finally, Accel Wealth Management increased its position in Aurinia Pharmaceuticals shares by 309.3% in the second quarter. Accel Wealth Management now owns 1,985 shares of the biotech company valued at $ 26,000 after acquiring an additional 1,500 shares in the last quarter. Hedge funds and other institutional investors hold 38.71% of the company’s shares.
Aurinia Pharmaceuticals Company Profile
Aurinia Pharmaceuticals Inc, a biopharmaceutical company, develops and markets therapies to treat various diseases with unmet medical needs in Japan and China. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and licensing agreement with Otsuka Pharmaceutical Co, Ltd.
Recommended story: cost of debt
This instant news alert was powered by storytelling technology and financial data from MarketBeat to provide readers with the fastest, most accurate reports. This story was reviewed by the MarketBeat editorial team before publication. Please send any questions or comments about this story to [email protected]
Should you invest $ 1,000 in Aurinia Pharmaceuticals now?
Before you consider Aurinia Pharmaceuticals, you’ll want to hear this.
MarketBeat tracks Wall Street’s top-rated and top-performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts quietly whisper to their clients to buy now before the broader market takes hold … and Aurinia Pharmaceuticals was not on the list.
While Aurinia Pharmaceuticals currently has a “Buy” rating among analysts, top-rated analysts believe these five stocks are better bets.
See the 5 actions here